Status:

RECRUITING

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Lead Sponsor:

Eli Lilly and Company

Conditions:

Ulcerative Colitis

Ulcerative Colitis Chronic

Eligibility:

All Genders

2-19 years

Phase:

PHASE3

Brief Summary

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

Eligibility Criteria

Inclusion

  • Participants from originating studies (I6T-MC-AMBA \[NCT05784246\], I6T-MC-AMBU \[NCT04004611\], I6T-MC-AMAM \[NCT03926130\]) , I6T-MC-AMAY \[NCT05509777\]) who would, in the opinion of the investigator, derive clinical benefit from further treatment with mirikizumab
  • Participants from prior studies who have completed assessments and procedures at last visit of originating study and remain on study drug treatment.
  • Female participants must agree to contraception requirements.

Exclusion

  • Participants must not have developed a serious adverse event (SAE) or Adverse Event (AE) in originating study or developed other condition before first visit of Study AMAZ that continued treatment with mirikizumab would present an unreasonable risk for the participant.
  • Participants must not have had permanently or temporarily stopped study drug in the originating study, such that restarting mirikizumab would pose an unacceptable risk for the participant in Study AMAZ.
  • Participants must not have an unstable or uncontrolled illness that would potentially affect participant safety.
  • Participants must not be enrolled in the study if, for any reason, being in the study would compromise the participant's safety or confound data interpretation.
  • Participants must not have adenomatous polyps that have not been removed.
  • Participants must not be pregnant or breastfeeding.

Key Trial Info

Start Date :

May 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2030

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT04844606

Start Date

May 26 2021

End Date

December 1 2030

Last Update

December 24 2025

Active Locations (59)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (59 locations)

1

UCSF Medical Center at Mission Bay

San Francisco, California, United States, 94158

2

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

3

Emory University School of Medicine

Atlanta, Georgia, United States, 30322

4

Children's Center for Digestive Health Care, LLC

Atlanta, Georgia, United States, 30342